Originally posted by MG.
I think what may have happened here is lots of retail have sold and moved on which is great for the company. Also traders who came in for a ride also sold out and moved on. Today's close is a very good sign up by 1c to 43c. Register has to tighten up now as no shares are sold under 40c and as a matter of fact mostly around 50c as VWAP yesterday close was close to 51c. Lots of Dixon's followers will keep buying. Its silly to sell now as the sell side is fuc*allleft and buyers willing to buy no matter whether Fed raised rates or Wall Street fell heavily or FiJi Kava by PAC totally tanked today on ASX. That must be the strength of Dixon's followers as they trust him and this LEAP thingy all the way and be loyal no matter what. Unreal is all I can say that in this market what EX1 has achieved is beyond belief. Lots of people said this has traits of A3D in its early days when it went from 20c to eventually $5+, I reckon they are on the money with their assessment. Even Alto will tell you that this is the best ever deal they ever done including A3D! Good on ya Dixon and EX1 Team and Alto. You all deserve credit for your achievements in this absolute shitty markets for IPO's. EX! is the stand out followed by runner up EMV in recent memory.Cheers
Hardly any "retail" would have got any. Was not an open IPO.
Those who mentioned CYP, that first run was on GMP where the cells were proven to be manufactured at a scalable level safely.
Stock ran from 39-40c to $1.44. (and all the way back once punters realized you still need human trials)
EX1 are wanting to also get to GMP soon, so this could be a big catalyst 2019. EX1 also have about the same SOI as CYP at same stage.
The big advantage for Exopharm, is the "juice" (good stuff) from the cell itself can be extracted with the LEAP technology, and the advantage there is transportation and delivery (cells need freezing)....so I would say EX1 is looking to be a GEN 3 technology in the rapidly developing stem cell therapy market.
GEN 1 being bone marrow harvesting (MSB)
CYP (GEN 2) has been the best performing Biotech in this MCap starting category ($10-$50m) over last 2.5 years at 232% (max over 400%) and holding.
Might give you some idea where this can go given founder and technology.
